HuGE Literature Finder
Records
1
-
30
| The frequencies of CYP2D6 alleles and their impact on clinical outcomes of adjuvant tamoxifen therapy in Syrian breast cancer patients. BMC cancer 2022 Oct 22 (1): 1067. Ismail Al-Khalil Wouroud, Al-Salhi Lana, Rijjal Sara, Aljamali Majd, Youssef Lama |
| Flexible Etherified and Esterified Triphenylethylene Derivatives and Their Evaluation on ER-positive and Triple-Negative Breast Cancer Cell Lines. ChemMedChem 2022 Jan e202100720. Hassan Aya S, Wober Jannette, Vollmer Günter, Abadi Ashraf H, Ahmed Nermin |
| Association between genetic polymorphisms in cytochrome P450 enzymes and survivals in women with breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Expert reviews in molecular medicine 2022 1 24 e1. Chan Carmen Wing Han, Li Caixia, Xiao Eleven Jinnan, Li Minjie, Phiri Patrick Gladson McLeywick, Yan Tingting, Chan Judy Yuet |
| A Population Pharmacokinetic Meta-Analysis of Veliparib, a PARP Inhibitor, Across Phase 1/2/3 Trials in Cancer Patients. Journal of clinical pharmacology 2021 Apr . Stodtmann Sven, Nuthalapati Silpa, Eckert Doerthe, Kasichayanula Sreeneeranj, Joshi Rujuta, Bach Bruce A, Mensing Sven, Menon Rajeev, Xiong H |
| Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer 2021 Mar 7 (1): 34. DeCensi Andrea, Johansson Harriet, Helland Thomas, Puntoni Matteo, Macis Debora, Aristarco Valentina, Caviglia Silvia, Webber Tania Buttiron, Briata Irene Maria, D'Amico Mauro, Serrano Davide, Guerrieri-Gonzaga Aliana, Bifulco Ersilia, Hustad Steinar, Søiland Håvard, Boni Luca, Bonanni Bernardo, Mellgren Gunn |
| Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse. Scientific reports 2021 Jan 11 (1): 415. Sanchez-Spitman A B, Swen J J, Dezentjé V O, Moes D J A R, Gelderblom H, Guchelaar H |
| Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: A propensity-score matched cohort study. International journal of cancer 2021 12 150 (10): 1664-1676. Zhou Weihang, Jiang Yiwei, Xu Yaqian, Wang Yaohui, Ma Xiaowei, Zhou Liheng, Lin Yanping, Wang Yan, Wu Ziping, Li Min, Yin Wenjin, Lu Jinso |
| Enriching Medication Review with a Pharmacogenetic Profile - A Case of Tamoxifen Adverse Drug Reactions. Pharmacogenomics and personalized medicine 2021 14 279-286. Jeiziner Chiara, Stäuble Céline K, Lampert Markus L, Hersberger Kurt E, Meyer Zu Schwabedissen Henriette |
| Biochip-based approach for comprehensive pharmacogenetic testing. Drug metabolism and personalized therapy 2020 Dec . Ikonnikova Anna Yu, Filippova Marina A, Surzhikov Sergey A, Pozhitnova Victoria O, Kazakov Ruslan E, Lisitsa Tatiana S, Belkov Sergey A, Nasedkina Tatiana |
| Model-Based Quantification of Impact of Genetic Polymorphisms and Co-Medications on Pharmacokinetics of Tamoxifen and Six Metabolites in Breast Cancer. Clinical pharmacology and therapeutics 2020 Oct . Puszkiel Alicja, Arellano Cécile, Vachoux Christelle, Evrard Alexandre, Le Morvan Valérie, Boyer Jean-Christophe, Robert Jacques, Delmas Caroline, Dalenc Florence, Debled Marc, Venat-Bouvet Laurence, Jacot William, Dohollou Nadine, Bernard-Marty Chantal, Laharie-Mineur Hortense, Filleron Thomas, Roché Henri, Chatelut Etienne, Thomas Fabienne, White-Koning Melan |
| ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone. Progress in neuro-psychopharmacology & biological psychiatry 2020 Jul 110042. Ganoci Lana, Trkulja Vladimir, Živkovic Maja, Božina Tamara, Šagud Marina, Lovric Mila, Božina Na |
| Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. British journal of clinical pharmacology 2020 Jul . Thorén Linda, Lindh Jonatan D, Ackehed Gerd, Kringen Marianne Kristiansen, Hall Per, Bergh Jonas, Molden Espen, Margolin Sara, Eliasson Er |
| Tamoxifen-related endocrine symptoms in Chinese patients with breast cancer: Study protocol clinical trial (SPIRIT Compliant). Medicine 2020 Feb 99 (8): e19083. Chan Carmen Wing Han, Miaskowski Christine, McCarthy Alexandra, Waye Mary Miu Yee, Yeo Winnie, So Winnie Kwok Wai, Choi Kai Chow, Tsui Stephen Kwok Wing, Chan Judy Yuet |
| Synthesis of novel flexible tamoxifen analogues to overcome CYP2D6 polymorphism and their biological evaluation on MCF-7 cell line. Drug development research 2020 1 81 (4): 444-455. Ahmed Nermin S, Wober Jannet |
| The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience. Asian Pacific journal of cancer prevention : APJCP 2020 12 21 (12): 3619-3625. Malash Ibrahim, Mansour Osman, Shaarawy Sabry, Abdellateif Mona S, Omar Anan, Gaafer Rabab, Zekri Abdel-Rhaman N, Ahmed Ola S, Bahnassy Abe |
| The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer. Clinical and translational science 2019 Oct . Nardin Jeanine Marie, Schroth Werner, Almeida Thais Abreu, Mürdter Thomas, Picolotto Solane, Vendramini Evelyn Castillo Lima, Hoppe Reiner, Kogin Jenifer Primon, Miqueleto Diandra, de Moraes Silvia Dark Robaskievicz, Schwab Matthias, Pecoits-Filho Roberto Flavio, Brauch Hiltrud, Casali-da-Rocha José Claud |
| Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China. Clinical drug investigation 2019 Sep . Wei Xiaoxia, Sun Hong, Zhuang Jie, Weng Xiuhua, Zheng Bin, Lin Qiwang, Zhang Guifeng, Cai Jiaq |
| Plasma endoxifen and 4-hydroxytamoxifen levels in CYP2D6(C100T) carrying breast cancer patients and association with serum cholesterol. Toxicology and applied pharmacology 2019 Jun 114619. Chao Ta-Chung, Pan Wen-Chi, Tsai Yi-Fang, Chou Yueh-Ching, Liu Yu-Rong, Wang Sheng-Fan, Chen Ying-Jen, Soucek Pavel, Ueng Yune-Fa |
| Factors Affecting Tamoxifen Metabolism in Patients With Breast Cancer: Preliminary Results of the French PHACS Study. Clinical pharmacology and therapeutics 2019 Feb . Puszkiel Alicja, Arellano Cécile, Vachoux Christelle, Evrard Alexandre, Le Morvan Valérie, Boyer Jean-Christophe, Robert Jacques, Delmas Caroline, Dalenc Florence, Debled Marc, Venat-Bouvet Laurence, Jacot William, Suc Etienne, Sillet Bach Isabelle, Filleron Thomas, Roché Henri, Chatelut Etienne, White-Koning Melanie, Thomas Fabien |
| Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis. Cancer chemotherapy and pharmacology 2019 Jan 83 (1): 71-79. Bai Yu, Wu Hai-Wei, Zhang Yan-H |
| CYP2D6*3 (A2549del), *4 (G1846A), *10 (C100T) and *17 (C1023T) genetic polymorphisms in Iranian breast cancer patients treated with adjuvant tamoxifen. Biomedical reports 2018 Nov 9 (5): 446-452. Saghafi Fatemeh, Salehifar Ebrahim, Janbabai Ghasem, Zaboli Ehsan, Hedayatizadeh-Omran Akbar, Amjadi Omolbanin, Moradi Siava |
| Genetic polymorphisms of 3'-untranslated region of SULT1A1 and their impact on tamoxifen metabolism and efficacy. Breast cancer research and treatment 2018 Aug . Sanchez-Spitman A B, Dezentjé V O, Swen J J, Moes D J A R, Gelderblom H, Guchelaar Henk-J |
| Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. Pharmacogenomics 2018 Jul . Sim Sarah, Lövrot John, Lindh Jonatan D, Bergh Jonas, Xie Hanji |
| Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. International journal of cancer 2018 Jul . Lan Bo, Ma Fei, Chen Shanshan, Wang Wenna, Li Qiao, Fan Ying, Luo Yang, Cai Ruigang, Wang Jiayu, Yuan Peng, Zhang Pin, Li Qing, Xu Bing |
| Detection of Cytochrome P450 Polymorphisms in Breast
Cancer Patients May Impact on Tamoxifen Therapy Asian Pacific journal of cancer prevention : APJCP 2018 Feb 19 (2): 343-350. Thota Kanakaiah, Prasad K, Basaveswara Rao Mandava |
| CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast cancer research : BCR 2018 12 20 (1): 149. Brooks Jennifer D, Comen Elizabeth A, Reiner Anne S, Orlow Irene, Leong Siok F, Liang Xiaolin, Mellemkjær Lene, Knight Julia A, Lynch Charles F, John Esther M, Bernstein Leslie, Woods Meghan, Doody David R, , Malone Kathleen E, Bernstein Jonine |
| Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics. Advances in pharmacology (San Diego, Calif.) 2018 83 65-91. Cronin-Fenton Deirdre P, Damkier P |
| The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. International journal of cancer 2018 07 143 (1): 184-189. Lan Bo, Ma Fei, Zhai Xiaoyu, Li Qiao, Chen Shanshan, Wang Jiayu, Fan Ying, Luo Yang, Cai Ruigang, Yuan Peng, Zhang Pin, Li Qing, Xu Bing |
| Variations in plasma concentrations of tamoxifen metabolites and the effects of genetic polymorphisms on tamoxifen metabolism in Korean patients with breast cancer. Oncotarget 2017 Nov 8 (59): 100296-100311. Woo Hye In, Lee Se Kyung, Kim Jiyoung, Kim Seok Won, Yu Jonghan, Bae Soo Youn, Lee Jeong Eon, Nam Seok Jin, Lee Soo-Yo |
| Polymorphism of the CYP2D6 gene in women with breast cancer treated with tamoxifen. European journal of gynaecological oncology 0 37 (5): 700-702. de Vasconcelos-Valenca R J, Melo M A, Lima E, de Sousa G V, Nazario A C, da Siilva B |
- Page last reviewed:Feb 1, 2023
- Page last updated:Feb 07, 2023
- Content source: